Skip to main content

Table 1 Characteristics of the studies included in the meta-analysis

From: The efficacy and safety of Iodine-131-metaiodobenzylguanidine therapy in patients with neuroblastoma: a meta-analysis

Year

Name of First Author

Country

Trial design

Schedule

Response criteria

Patients Enrolled

Tumor response

CR/PR

SD

PD

MR

1991

Hutchinson [28]

NSa

Single-arm Phase I

Doses ranged from 50-220 mCi, with cumulative doses of 50-654 mCi in one to three doses

 

14

4

-

-

2

1991

Klingebiel [29]

Germany

NS

NS

NS

47

9

-

-

-

1991

Matthay [30]

NS

Single-arm Phase I

100-400 mCi/m2/course

 

11

2

2

7

0

1991

Troncone [31]

Italy

Single-arm Phase I

single doses (2.6-9.5 GBq)

 

11a

2

4

2

1

1992

Lashford [24]

UK

Single-arm Phase I

NS

ENSG Criteri a[24]

25

8

9

7

-

1994

Hoefnagel [14]

Netherlands

Single-arm Phase II

First 200mCi,

If necessary, more cycles with100mCi at 4 weeks intervals

NS

31

22

8

-

-

1995

de Kraker [15]

Netherlands

Single-arm Phase II

First 200mCi,

If necessary, more cycles with100mCi at 4-6 weeks intervals

INR C[32]

33

19

11

3

-

1999

Garaventa [17]

Italy

Single-arm Phase II

67.5-148mCi

1-5 courses

INRC

43

13

-

5

25

2005

Howard [18]

USA

Single-arm Phase II

3-19mCi/kg

2 to 4 courses

INRC

28

11

8

8

1

2007

Matthay [19]

USA

Single-arm Phase II

12 or 18mCi/kg

INRC

164

59

55

44

5

2008

de Kraker [23]

Netherlands

Single-arm Phase II

200 mCi for the first infusion and 100–150 mCi for the second and all subsequent infusions.

INRC

41b

27

5

4

4

2009

Matthay [20]

USA

Single-arm Phase I

Day 0 and day 14, 12-21mCi/kg

RECIS T[33]

20

10

3

7

8

2011

Johnson [21]

USA

Single-arm Phase II

18mCi/kg

If necessary, additional 18mCi/kg were received within 100 days.

INRC

117

35

52

30

-

2011

Mastrangelo [34]

Italy

Pilot study

131I-MIBG combined with other therapies

INRC

13

6

-

-

1

2011

Polishchuk [22]

USA

Single-arm Phase II

17.8 millicuries (mCi)/kg

INRC

39

18

17

2

2

2012

DuBois [35]

USA

Single-arm Phase I

131I-MIBG combined with other therapies

NANT Response Criteri a[35]

24

6

-

-

-

2013

Kushner [36]

USA

NS

131I-MIBG combined with other therapies

INRC

3

1

2

0

0

2015

DuBois [37]

USA

Single-arm Phase I, II

131I-MIBG combined with other therapies

NANT Response Criteria

32

9

-

-

-

2015

DuBois [38]

USA

Single-arm Phase I

131I-MIBG combined with other therapies

NANT Response Criteria

27

7

-

-

-

2015

Kraal [39]

Netherlands

Single-arm Phase II

131I-MIBG combined with other therapies

INRC

16

9

-

-

-

2015

Yanik [40]

USA

Single-arm Phase II

131I-MIBG combined with other therapies

INRC

49

7

26

6

10

2016

George [41]

UK

NS

131I-MIBG monotherapy

INRC

25

15

8

-

-

2016

Modak [42]

USA

Single-arm Phase II

131I-MIBG combined with other therapies

INRC

19

0

-

7

-

2019

Genoll a[43]

Spain

NS

131I-MIBG combined with other therapies

INRC, RECIST

10

7

2

1

0

2020

Anongpornjossakul [44]

Thailand

NS

mean dose of 136 mCi per treatment

RECIST 1.1 [45]

22

7

3

12

0

2020

Kayano [46]

Japan

NS

single dose of 444 to 666 MBq/kg

RECIST 1.1

19b

5

10

3

0

  1. a: 2 patients were not evaluable. b: 1 patient was not evaluable. NS: Not specified. RECIST, Response Evaluation Criteria in Solid Tumors.
  2. INRC the International Neuroblastoma Response Criteria. NANT the New Approaches to Neuroblastoma Therapy. ENSG European Neuroblastoma Study Group